Clinical trials: Early-Stage Lung Cancer
Stage IA Lung Cancer
Transbronchial vs Transthoracic Ablation for Early-stage Peripheral Lung Cancer
The purpose of this study is to investigate the efficacy and safety of RFA through a transthoracic or transbronchial approach in the treatment of early-stage peripheral lung cancer.
- Trial name
- NCT06052098
- Testing
- The disposable pulmonary radiofrequency ablation catheter and pulmonary radiofrequency ablation system, The disposable percutaneous radiofrequency ablation needle and pulmonary radiofrequency ablation system
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Hangzhou Broncus Medical Co., Ltd.
Limited Stage Small Cell Lung Cancer
Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
This phase 2 trial examined whether the preliminary efficacy and safety of ociperlimab, tislelizumab, and cCRT when used in combination is expected to advance treatment options in the serious unmet medical need population of…
- Trial name
- NCT04952597
- Testing
- Ociperlimab, Tislelizumab, Concurrent Chemoradiotherapy
- Where
- 33 sites in United States, China and 1 more
- Volunteers
- 126 people
- Sponsor
- BeiGene
Lung Cancer (Diagnosis)
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
Evaluate FlowPath Lung Diagnostic Test of Sputum Samples to Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, >6 to <30 mm in Diameter, Determined by LDCT.
- Trial name
- BA-004 (NCT07168993)
- Testing
- Standard medical treatment
- Where
- 11 sites in United States
- Volunteers
- 2,063 people
- Sponsor
- bioAffinity Technologies Inc.
Myelosuppression
A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer
The primary goal of this study is to evaluate the myelo-protective effect and safety of Trilaciclib in participants with limited stage small cell lung cancer (LS-SCLC) who are receiving concurrent chemo-radiotherapy.
- Trial name
- TRACER (NCT07881705)
- Testing
- Trilaciclib, Etoposide Injection, Carboplatin or Cisplatin Injection
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer, NSCLC
A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced
This is a non-interventional, retrospective observational study to improve knowledge regarding the diagnosis and treatments of patients who have/had non-small cell lung cancer (NSCLC), either early stage (stage I-II).
- Conditions
- Non-small Cell Lung Cancer, NSCLC, NSCLC, Stage III, NSCLC, Stage I
- Trial name
- Key-Early (NCT06467383)
- Where
- 25 sites in Italy
- Volunteers
- 600 people
- Sponsor
- MSD Italia S.r.l.
Non-Small Cell Lung Cancer
Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer
The purpose of this trial is to examine the safety and immunogenicity of a therapeutic vaccine regimen with recombinant DNA and adenovirus expressing L523S protein in patients with early stage non-small cell lung cancer.
- Trial name
- NCT00062907
- Testing
- Recombinant DNA- pVAX/L523S, Recombinant adenovirus- Ad/L523S
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Corixa Corporation
NSCLC, Non Small Cell Lung Cancer
A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer
For patients diagnosed with early (Stage I) non-small cell lung cancer, a lobe of lung is usually removed at surgery to treat the cancer.
- Trial name
- NCT01237171
- Testing
- Cesium-131 Brachytherapy Seed
- Where
- United States
- Sponsor
- IsoRay Medical, Inc.
Small Cell Lung Cancer
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed…
- Trial name
- ADRIATIC (NCT03703297)
- Testing
- Durvalumab, Tremelimumab
- Where
- 183 sites in United States, Argentina and 17 more
- Volunteers
- 730 people
- Sponsor
- AstraZeneca
Limited-stage Small-cell Lung Cancer
A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer
This study will evaluate the efficacy, safety and tolerability of HS-20093 compared with active surveillance as consolidation therapy after chemoradiotherapy in participants with limited-stage small cell lung cancer.
- Trial name
- NCT06526624
- Testing
- HS-20093
- Volunteers
- 406 people
- Sponsor
- Hansoh BioMedical R&D Company
Carcinoma, Non-Small-Cell Lung
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II…
- Trial name
- PACIFIC-4 (NCT03833154)
- Testing
- Durvalumab, (Osimertinib cohort, single-arm, open-label separate cohort)
- Where
- 209 sites in United States, Australia and 18 more
- Volunteers
- 724 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung Cancer
This is a non-interventional, multi-country, multicentre, retrospective study designed to determine the treatment patterns and associated survival rate in patients with primary stage IA to IIIB resectable NSCLC diagnosed between…
- Trial name
- THASSOS-INTL (NCT04808050)
- Where
- 25 sites in Australia, Egypt and 5 more
- Volunteers
- 748 people
- Sponsor
- AstraZeneca
Lung Cancer, NSCLC
Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)
This registry is intended to measure the effect of myPlan Lung Cancer™ test has on influencing treatment decisions of Oncologists when added to standard clinical-pathological parameters in patients with early stage NSCLC.
- Conditions
- Lung Cancer, NSCLC, NSCLC Adenocarcinoma
- Trial name
- ONC006 (NCT02121899)
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Non-small Cell Lung Cancer
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
This is a study to evaluate the effectiveness of erlotinib compared with a placebo sugar pill following complete surgical removal of the tumor with or without chemotherapy after surgery in Stage IB-IIIA NSCLC patients.
- Trial name
- RADIANT (NCT00373425)
- Testing
- Erlotinib
- Where
- 295 sites in United States, Argentina and 17 more
- Volunteers
- 1,252 people
- Sponsor
- OSI Pharmaceuticals
NSCLC
Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC
A prospective, single-arm, non-randomized, multi-center, open-label study following patients with resectable stage IIB to IIIA non-small cell lung cancer after Pulsed Electric Fields (PEF) ablation who may be candidates for…
- Trial name
- VIGOR (NCT05583188)
- Testing
- Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Standard of care neoadjuvant therapy
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Galvanize Therapeutics, Inc.
Small Cell Lung Cancer Limited Stage
A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients
This study is a randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of TQB2450 in combination with anlotinib as maintenance therapy in patients with limited-stage small cell…
- Trial name
- NCT06469879
- Testing
- TQB2450+Anlotinib
- Where
- 16 sites in China
- Volunteers
- 358 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Lung Cancer, Small Cell, Small Cell Lung Cancer
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
This study will gather information on the effectiveness and safety of a treatment program for small cell lung cancer (SCLC) that uses an FDA approved chemotherapy combination, radiation therapy, and an oral investigational drug…
- Trial name
- (SCLC) (NCT00043862)
- Testing
- topotecan
- Where
- 31 sites in United States
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer…
- Trial name
- NCT07195695
- Testing
- Zongertinib, Pembrolizumab, Atezolizumab
- Where
- 202 sites in United States, Argentina and 26 more
- Volunteers
- 400 people
- Sponsor
- Boehringer Ingelheim
Small-cell Lung Cancer
a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.
The study is being conducted to evaluate the efficacy and safety of QL1706 versus QL1604 monotherapy as consolidation treatment in patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced disease…
- Trial name
- NCT06789796
- Testing
- Iparomlimab and Tuvonralimab (QL1706), QL1604
- Volunteers
- 636 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in…
- Trial name
- NeoCOAST-2 (NCT05061550)
- Testing
- Durvalumab, Oleclumab, Monalizumab
- Where
- 97 sites in United States, Belgium and 10 more
- Volunteers
- 630 people
- Sponsor
- AstraZeneca
Limited Stage Small-Cell Lung Cancer
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
This prospective, multicentre, observational study aims to assess the effectiveness and safety of durvalumab as consolidation treatment for patients with LS-SCLC who have not progressed following CRT in real-world setting.
- Trial name
- DREAM (NCT07161388)
- Where
- 21 sites in China
- Volunteers
- 200 people
- Sponsor
- AstraZeneca